Every moment counts when treating a patient with a heart attack.

About zalunfiban

Zalunfiban is an investigational next-generation GPIIb/IIIa platelet inhibitor that was specifically designed for pre-hospital treatment of STEMI heart attacks and is injected subcutaneously (under the skin).

Zalunfiban reaches maximal effect within 15 minutes and its antiplatelet effect wears off in about two hours. 1[1] Bentur OS, et al. Assessing the Pharmacodynamics of RUC-4 (zalunfiban), a Novel αIIbβ3 Antagonist, Using VerifyNow Assays in Patients with ST-Segment Elevation Myocardial Infarction (STEMI) Treated with Aspirin and Ticagrelor [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 1).

About zalunfiban

Zalunfiban is an investigational agent; it has not been approved for any use and its safety and efficacy have not been established.

Most STEMI patients aren't treated within recommended time guidlines
Download image Expand image

Addressing the time-to-treatment gap

Download image Expand image

Potential for rapid heart attack treatment in multiple pre-PCI settings

About Us

Each year, 800,000 people in the United States have an acute myocardial infarction (AMI), or heart attack. We founded CeleCor Therapeutics to improve the treatment of ST-Segment Elevated Myocardial Infarctions (STEMI heart attacks) at the first point of medical contact.

More about us
Close